Target 2035 – update on the quest for a probe for every protein
文献信息
Susanne Müller, Suzanne Ackloo, Arij Al Chawaf, Hartmut Beck, Shaunna Beedie, Ulrich A. K. Betz, Gustavo Arruda Bezerra, Paul E. Brennan, David Brown, Peter J. Brown, Alex N. Bullock, Adrian J. Carter, Apirat Chaikuad, Mathilde Chaineau, Alessio Ciulli, Ian Collins, Jan Dreher, Kristina Edfeldt, Aled M. Edwards, Ursula Egner, Stephen M. Fuchs, Matthew D. Hall, Ingo V. Hartung, Alexander Hillisch, Stephen H. Hitchcock, Evert Homan, Natarajan Kannan, James R. Kiefer, Stefan Knapp, Milka Kostic, Stefan Kubicek, Andrew R. Leach, Sven Lindemann, Hisanori Matsui, Jordan L. Meier, Maurice Michel, Maxwell R. Morgan, Anke Mueller-Fahrnow, Dafydd R. Owen, Benjamin G. Perry, Saul H. Rosenberg, Kumar Singh Saikatendu, Cora Scholten, Sujata Sharma, Anton Simeonov, Michael Sundström, Matthew H. Todd, Claudia Tredup, Timothy M. Willson, Georg E. Winter
Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome is still fragmented. The challenge of translating the wealth of new knowledge from genomics into new medicines is that proteins, and not genes, are the primary executers of biological function. Therefore, much of how biology works in health and disease must be understood through the lens of protein function. Accordingly, a subset of human proteins has been at the heart of research interests of scientists over the centuries, and we have accumulated varying degrees of knowledge about approximately 65% of the human proteome. Nevertheless, a large proportion of proteins in the human proteome (∼35%) remains uncharacterized, and less than 5% of the human proteome has been successfully targeted for drug discovery. This highlights the profound disconnect between our abilities to obtain genetic information and subsequent development of effective medicines. Target 2035 is an international federation of biomedical scientists from the public and private sectors, which aims to address this gap by developing and applying new technologies to create by year 2035 chemogenomic libraries, chemical probes, and/or biological probes for the entire human proteome.
相关文献
A single-bead telomere sensor based on fluorescence resonance energy transfer
Xiao Fan, Qiaoli Yue, Yanyan Li, Yingya Liu, Lu-Lu Qu, Yingnan Cao
DOI: 10.1039/C5AN02543E
Proteomic and direct analysis in real time mass spectrometry analysis of a Native American ceremonial hat
Timothy P. Cleland, G. Asher Newsome, R. Eric Hollinger
DOI: 10.1039/C9AN01557D
A magnetic nanoparticle-based aptasensor for selective and sensitive determination of lysozyme with strongly scattering silver nanoparticles
Chun Mei Li, Lei Zhan, Lin Ling Zheng, Yuan Fang Li
DOI: 10.1039/C6AN00489J
Screening of DNA G-quadruplex stabilizing ligands by nano differential scanning fluorimetry
Bruno Pagano, Nunzia Iaccarino, Anna Di Porzio, Antonio Randazzo, Jussara Amato
DOI: 10.1039/C9AN01463B
Correction: Micropatterning neuronal networks
Heike Hardelauf‡, Sarah Waide‡, Julia Sisnaiske, Peter Jacob, Vanessa Hausherr, Nicole Schöbel, Dirk Janasek, Christoph van Thriel
DOI: 10.1039/C6AN90037B
Semi-automatic instrumentation for nucleic acid extraction and purification to quantify pathogens on surfaces
Won-Nyoung Lee, Hyun Jin Yoo, Kim Huyen Nguyen, Changyoon Baek, Junhong Min
DOI: 10.1039/C9AN00896A
Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer
Areti Strati, Martha Zavridou, Evangelos Bournakis, Sophia Mastoraki, Evi Lianidou
DOI: 10.1039/C9AN00999J
Investigating the effect of Ag nanocube polydispersity on gap-mode SERS enhancement factors
Tyler J. Dill, Matthew J. Rozin, Eric R. Brown, Stephen Palani, Andrea R. Tao
DOI: 10.1039/C6AN00212A
Electrochemical performance of ruthenium nanoparticles decorated on nitride carbon for non-enzymatic detection of hydrogen peroxide
Xia Cheng, Caili Xu, Qian Chen, Yi Wang, Yun Zhang, Guangyin Fan
DOI: 10.1039/C9AN01480B
您可能还喜欢
什么是2-氨基戊烷(CAS号:63493-28-7)?
2-氨基戊烷,又名pentan-2-amine,是一种有机化合物,分子式为C5H11NH2。它是一种无色透明液体,有氨味。该化合物在工业和研究中有一定的应用。
反式-4-[4-[[[5-[(3,4-二氟苯基)氨基]-1,3,4-恶二唑-2-基]羰基]氨基]苯基]环己烷乙酸(CAS号:892489-52-0)的物理化学性质是什么?
该化合物为白色固体,分子量为552.31 g/mol。它在水中溶解度较低,在有机溶剂如乙腈、乙酸乙酯中有较好的溶解性。该化合物具有较高的化学稳定性,对酸和碱具有...
如何处理含有Pyrotinib dimaleate(CAS号:1397922-61-0)的废料?
处理含有Pyrotinib dimaleate 的废料时,应遵循当地的法规要求。首先,收集废料并进行分类,确保没有与其他化学品混合。然后,采取适当的物理和化学处...
在合成中是否有4-(5-5-乙基-1,2,4-噁二唑-3-基)苯甲酸乙酯(CAS号:1166756-79-1)的替代品?
在合成过程中,可以考虑使用其他结构类似的化合物作为替代品,例如苯甲酸酯类化合物,如2-乙基-5-甲基噁二唑基苯甲酸乙酯等。这些替代品可能具有相似的化学性质,但在...
如何处理含有1-((叔丁氧基羰基)氨基)环丁烷甲酸甲酯(CAS号:880166-10-9)的废料?
处理含有该化合物的废液时,应先确保其完全反应并转化为无害物质。对于未反应的化合物,建议采用中和处理后进行蒸馏回收,剩余物可使用化学氧化法或焚烧法进行无害化处理。...
2-({[3,5-二(三氟甲基)苯基]磺酰基}氨基)-4-(甲基硫代)丁酸甲酯(CAS号:175202-21-8)的市场或研究趋势如何?
目前该化合物主要应用于药物合成领域,尤其在开发新型抗癌药物方面具有潜在应用。随着制药行业的持续发展,对于高效、低毒的合成中间体需求增加,预计该化合物的研究和应用...
N,N-乙烯双(碘乙酰胺)(CAS号:7250-43-3)的物理化学性质是什么?
N,N-乙烯双(碘乙酰胺)是一种白色或类白色固体,易溶于乙醇、丙酮等有机溶剂,但在水中溶解度较低。该化合物具有较高的反应活性,可以与其他含有活性氢的化合物发生酰...
7-Fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine](CAS号:1283090-73-2)通常如何合成?
该化合物可以通过环合反应合成,首先合成吡啶和哌啶的衍生物,然后在合适的条件下进行环合反应得到目标化合物。常用的催化剂包括某些金属盐类,产率一般在70%-90%之...
处理3-乙酰滇乌碱(CAS号:80787-51-5)时应注意哪些实验室安全事项?
在处理3-乙酰滇乌碱时,应穿戴适当的个人防护装备(PPE),如实验服、手套(丁腈手套或PVC手套)、护目镜和口罩。实验应在通风橱中进行,以减少吸入或皮肤接触的风...
如何储存2-溴-5-硝基-4-羧酸(CAS号:1053655-82-5)?
2-溴-5-硝基-4-羧酸应存放在阴凉、干燥、通风良好的地方,远离火源和热源。避免与还原剂、碱性物质接触。储存容器应密封,防止吸湿。











![Benzo[b]naphtho[2,1-d]thiophene structure Benzo[b]naphtho[2,1-d]thiophene structure](https://cnstatic.chemtradehub.com/structs/239/239-35-0-ff90.webp)



